Explore every episode of the podcast The Biotech Voyager

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities and emerging technologies. From AI-powered antibody discovery to neutrophil cell therapies, the conversation spans cutting-edge innovation while maintaining critical scientific scrutiny. The episode opens with Big Hat Biosciences' impressive $75 million Series C raise, examining their AI-driven platform for antibody drug conjugate development. The hosts explore how Big Hat's cyclical approach integrates automated wet lab experimentation with AI analysis to iteratively improve therapeutic candidates. The discussion contextualizes AI's role in drug discovery, distinguishing between AI for molecular design versus AI for data analysis and experimental optimization. With backing from major pharmaceutical companies including Amgen, BMS, Eli Lilly, and Merck, and fresh patient dosing in Phase I trials, Big Hat represents a significant validation signal for AI-enabled therapeutic development. The conversation continues with Basecamp Research's massive $140 million Series C, exploring their Eden AI model trained on 9.7 trillion nucleotide tokens from ethically sourced genomic data across 30+ countries. The hosts examine how this comprehensive genetic diversity dataset could enable more effective in vivo CAR-T therapies for solid tumors by identifying candidates with broader patient population applicability. The discussion probes the technical challenges of translating genomic data into functional therapeutics while acknowledging the ambitious nature of in vivo cell therapy approaches. Additional signals include AvenCell's $47 million raise for their universal switchable CAR-T platform, which achieved 71% overall response rates in relapsed/refractory AML using adapter molecules that can target multiple antigens. The hosts examine Scarlet Therapeutics' DARPA-funded program developing smart red blood cells that sense environmental conditions and deliver therapeutics accordingly. Lyft Therapeutics emerges from rebranding with neutrophil cell therapies, though the hosts express significant skepticism about the six to twelve hour lifespan challenge inherent to neutrophil-based therapeutics. AC Immune's active immunotherapy for Parkinson's demonstrates 100% antibody response rates at 100 weeks, prompting debate about terminology distinctions between vaccines and active immunotherapies. The episode features an interview with Ryan from LabThread discussing laboratory software challenges and the future of lab automation, followed by examination of Anthropic's Claude-led discovery of a potential new gene editing mechanism and the A16Z Academy as an alternative to traditional university education for aspiring biotech professionals. Listeners will gain insight into how AI is transforming both therapeutic development and laboratory operations, the critical importance of therapeutic lifespan in cell therapy design, the evolving role of government funding through programs like DARPA and ARPA-H, and why the distinction between prophylactic vaccines and therapeutic active immunotherapies matters for understanding emerging modalities. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #AI #drugdiscovery #CARTtherapy #genetherapy #antibodies #celltherapy #activeimmunotherapy #labautomation

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities. From gene therapies that transform the liver into drug factories to innovative biomaterials that dissolve over time, the conversation spans the cutting edge of biotechnology innovation. The episode opens with an in-depth analysis of ViroNexus, a company developing a revolutionary AAV-based gene therapy for acute lymphoblastic leukemia. Rather than infusing T-cell engagers directly, ViroNexus delivers a transgene that transforms hepatocytes into factories that continuously produce and secrete these therapeutics into the bloodstream. The hosts examine the striking 100% response rate at nine months in three patients, while carefully contextualizing both the promise and significant questions surrounding this biofactory approach. The discussion explores a critical challenge: how do you turn off a therapeutic that's designed to produce drugs for years when targeting healthy B cells could lead to prolonged immunosuppression? The conversation moves through Acro Biosciences' selective RIPK2 inhibitor for ulcerative colitis, examining how targeted inhibition of inflammatory signaling cascades offers straightforward solutions to complex diseases. The hosts then explore Biactica's non-PROTAC oral protein degrader for glioblastoma, highlighting how this orally bioavailable, blood-brain barrier-crossing therapeutic represents a new frontier in targeting previously undruggable proteins through degradation rather than inhibition. Additional signals include Anixa's dual approach combining cancer vaccines with chimeric endocrine receptor therapy for breast cancer, Dualitas' bispecific antibodies that achieve synergistic effects by targeting proximal cell surface proteins, and Dialibrid's innovative silk-polyurethane biomaterial that provides structural support for cell therapies before dissolving over time. The episode concludes with a paper of the day segment examining dual-targeted CAR-T approaches for glioblastoma that simultaneously eliminate both tumor cells and the immunosuppressive myeloid shield. Listeners will gain insight into the promise and challenges of biofactory therapeutics, the expanding toolkit of protein degradation technologies, the importance of controllable expression systems in gene therapy, and why targeting the tumor microenvironment may be as critical as targeting cancer cells themselves. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #genetherapy #proteindegraders #glioblastoma #bispecificantibodies #biomaterials #celltherapy

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts examine a striking clinical trial result that has generated significant attention in the cell therapy and oncology communities. The discussion centers on a therapeutic approach that has achieved a 100% response rate at nine months in early patient data, a result that stands out dramatically even in a field that has seen remarkable advances in recent years. The conversation explores both the promise and the important caveats surrounding this data. While a 100% response rate represents an extraordinary outcome compared to existing therapies where 70% response rates are considered exceptional, the hosts carefully contextualize this finding within the reality of early clinical development. The result comes from just three patients, making it a preliminary signal rather than definitive proof of efficacy. The discussion examines what constitutes meaningful evidence in early-stage trials and how to interpret small patient cohorts while maintaining appropriate scientific skepticism. The episode delves into the durability aspect of these responses, with patients showing sustained therapeutic benefit out to approximately 260 days following a single infusion. This durability is particularly noteworthy in the context of cell-based therapies, where persistence and long-term function remain critical challenges. The hosts also note the favorable safety profile, with no dose limiting toxicities observed in these initial patients, though questions remain about longer-term follow-up and broader patient populations. Listeners will gain insight into how to evaluate early-stage clinical data in cell therapy, the significance of response rates and durability in assessing therapeutic potential, and why promising preliminary results require careful interpretation before drawing definitive conclusions about clinical impact. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #celltherapy #clinicaltrials #oncology #immunotherapy #durability

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts dive deep into an innovative approach to cancer treatment that combines AI-driven drug discovery with population-level tumor modeling. The conversation explores how computational platforms are being used to identify novel drug combinations that could dramatically extend overall survival in cancer patients. The discussion centers on a groundbreaking methodology that tests hypotheses using AI to generate drug candidates, followed by synthesis and wet lab validation. This approach bridges both drug repurposing of approved combinations and the discovery of entirely new therapeutic strategies. The guest reveals an ambitious vision: extending overall survival by potentially three times through cleverly combined existing drugs and novel approaches. The episode examines the technical sophistication behind population-level cancer modeling, including the use of Mueller plots to visualize which tumor cell populations get eliminated and which resistant populations emerge over time. This granular view reveals both the promise and the challenge: while initial combinations can knock out 90% of tumor bulk, persistent resistant populations present an even greater therapeutic challenge. The conversation explores why achieving complete cancer resolution may require going beyond existing drugs to develop truly novel approaches. Listeners will gain insight into how AI and computational biology are transforming cancer drug development, the strategic balance between drug repurposing and novel discovery, and why understanding tumor population dynamics at high resolution is critical for developing next-generation combination therapies. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #AI #drugdiscovery #cancer #combinationtherapy #computationalbiology

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts explore a revolutionary approach to organ transplantation that could fundamentally transform how we think about tissue rejection and donor compatibility. The discussion centers on an innovative gene therapy technique that modifies donor organs before transplantation by removing the molecular markers that trigger immune rejection. The conversation examines the science behind HLA deletion, the key recognition system that T cells use to identify foreign tissue. The hosts walk through the technical process of soaking donor organs in viral mixtures containing CRISPR-based gene therapies designed to eliminate HLA markers from the organ surface. This approach creates what could be described as a "stealth organ" that evades immune detection, potentially eliminating the need for lifelong immunosuppression in transplant recipients. The episode delves into the implications of this technology for critical organs including hearts, livers, and kidneys. By removing the molecular signatures that distinguish one person's tissue from another, this approach could dramatically expand the donor pool and reduce transplant rejection rates. The discussion explores how gene editing technologies like CRISPR are being applied not just to individual cells but to entire organs, representing a significant leap in the practical application of gene therapy. Listeners will gain insight into how cutting-edge gene editing is being deployed to solve one of transplant medicine's most persistent challenges, the technical mechanisms behind immune recognition and evasion, and the potential for this approach to reshape organ transplantation in the coming years. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #CRISPR #organtransplantation #genetherapy #immunology #HLA

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they're big news.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Dan Tardiff, Chief Scientific Officer of CAMP4 Therapeutics, joins the show to explain how his company is using antisense oligonucleotides to upregulate gene expression by targeting regulatory RNAs, why haploinsufficient disorders represent the ideal therapeutic window for their platform, and why a modest twofold increase in transcription could transform treatment for rare neurodevelopmental diseases. CAMP4 has developed a novel approach to gene upregulation that targets non-coding regulatory RNAs transcribed from promoters and enhancers rather than the genes themselves. Dan walks through the biology of these regulatory elements, explaining how nearly universal transcription from promoters and enhancers creates a kinetic trap for transcription factors that can be modulated with antisense oligonucleotides. The platform uses genome-wide mapping techniques including chromatin accessibility, histone modifications, and Hi-C sequencing to identify regulatory regions, then confirms RNA expression through long-read sequencing before screening for therapeutic oligonucleotides. The conversation explores why ASOs offer advantages over small molecules and gene therapy for certain indications, how CAMP4's lead program in SYNGAP1-related disorder compares to Stoke Therapeutics' splice-switching approach in Dravet syndrome, the technical challenges of intrathecal delivery versus emerging blood-brain barrier shuttle technologies, and why the company expects to initiate Phase 1/2 clinical trials by the end of the year following regulatory approval in Australia and Argentina. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #CAMP4therapeutics #ASO #genetherapy #CNS #raredisease

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Rustam Esanov, co-founder and CEO of Reprogram Bio, joins the show to explain how his company is transforming cancer cells into allies rather than attacking them directly, why the convergence of single cell sequencing and mRNA delivery makes reprogramming therapeutics possible now, and why he believes reprogramming is the natural evolution of in vivo genetic medicine. Reprogram Bio is developing a novel approach to solid tumor therapy that uses mRNA to deliver master regulator transcription factors directly into tumors. Rather than trying to kill cancer cells or recreate a specific cell type like competitor Asgard Therapeutics, Reprogram Bio activates multiple therapeutic functions within cancer cells themselves, including antigen presentation, immune cell recruitment, and co-stimulation. Rustam walks through their lead program in colorectal and non-small cell lung cancer, explains how their approach differs from other tumor reprogramming strategies, and shares early results showing complete tumor eradication and resistance to cancer rechallenge in mouse models. The conversation explores the biological foundation of cellular reprogramming, the technical challenges of in vivo delivery, potential applications beyond oncology including Parkinson's disease and diabetes, and why reprogramming therapeutics represent the next frontier after in vivo CAR-T. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #reprogrambio #mRNA #celltherapy #oncology #immunotherapy

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.

Welcome to the Biotech Voyager w/ Jeff and Ben. It's the show that covers what's next in biotech.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they become big news.

Welcome to The Biotech Voyager, the show that covers what's next in biotech.

Jack Gugel, co-founder and CEO of Arkana Therapeutics, joins the show to explain how a molecule discovered in Burmese python metabolism could offer an alternative to GLP-1 drugs, why pythons are the perfect model organism for studying extreme metabolic swings, and why he thinks every PhD should end with a company instead of a postdoc application. Arkana spun out of a University of Colorado Boulder lab that's spent 20 years studying how Burmese pythons survive a year without eating, then consume a meal their own body weight, spiking their metabolism 40x in the process. That extreme biology led to the discovery of a novel appetite suppressant molecule that acts only on the brain, unlike GLP-1 drugs, which also slow gastric emptying and cause GI side effects in roughly half of patients. Jack walks through the science, the company's origin story, and where the platform goes next. Chapters 00:00:00 Intro and meet Jack Gugel, CEO of Arkana Therapeutics 00:01:03 How studying pythons for a PhD led to a biotech 00:02:45 The discovery: a python molecule that suppresses appetite 00:04:26 GLP-1 vs. Arkana's molecule, why the side effects differ 00:06:10 From 200 metabolites to one drug candidate 00:07:04 How they actually manufacture it (they're not farming pythons) 00:08:46 The origin story: an Oklahoma road trip and a CU Boulder lab 00:11:00 Why every PhD should end with a company 00:14:16 The eureka moment: a drug target with zero competition 00:16:06 The flip side: could this help cancer and ICU patients? 00:17:36 Arkana's next steps and funding stage 00:18:49 The other half of weight loss: burning calories like a python 00:20:27 Inside the lab: how they pull compounds from snakes 00:24:20 Other biotechs betting on extreme animal biology 00:25:47 What's being slept on in biotech right now New episodes every Tuesday and Thursday at 11:00 AM. #biotech #arkana #GLP1

Welcome to the BioTek Voyager. It's the show that covers what's next in BioTech, mapping the early-stage signals that are going to be a big deal in a couple years.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they become major news. If you have any questions, drop them below.

Welcome to The Biotech Voyager. It's the show that covers the early-stage biotech space, uncovering the companies that are going to be a big deal in a couple of years.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech. Drop a question in the chat to be part of the conversation .

Kevin Walton, CEO of Baseimmune, joins Ben and Jeff to break down one of the most underappreciated problems in modern medicine: fibrosis. IPF alone carries a life expectancy of three to five years upon diagnosis, and despite decades of research only three drugs have been approved, none of which halt or reverse the disease. Kevin explains why every previous approach has failed, why fibrosis is a network-driven redundant disease that defeats single-target therapies, and how Baseimmune's computational platform uses active immunotherapy to go after multiple pathways simultaneously with a single vaccine. Beyond fibrosis, Kevin reveals two additional applications the platform is being explored for, including a therapeutic vaccine for chronic pain and migraines, and a cardiovascular application. He also shares his take on what is most slept on in biotech right now: the immune system as a drug manufacturing platform. 0:00 Introduction 1:02 What is Baseimmune targeting with active immunotherapy 1:25 IPF — the disease, the stats, the failure of current drugs 1:49 Why single-target approaches keep failing 4:03 How the vaccine approach works 4:28 Additional applications beyond fibrosis 7:31 The data they've seen so far 9:35 Early results and what's encouraging 13:30 Pain vaccine — chronic migraines and the marketing opportunity 14:42 Cardiovascular applications 15:43 AI and the future of peptide-based immunotherapy 19:45 What's slept on in biotech — Kevin's answer 20:33 Immune system as a drug manufacturing platform 21:31 Jeff's response and closing thoughts New episodes every Tuesday and Thursday at 11:00 AM 🚀

Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Feel free to leave a comment, and we will get to it as quickly as we can.

Jonathan Cohen-Gold, CEO of Houdini Bio, joins Ben and Jeff to break down one of the most underappreciated problems in cell and gene therapy: cells don't like foreign DNA. When you deliver a therapeutic gene, the cell's innate immune system recognizes it as a threat and shuts it down. Houdini Bio's platform uses AI and proprietary Houdini elements, short 100 base pair sequences, to give the therapeutic DNA a self-hallmark, essentially camouflaging it against the cell's defense machinery without touching the pathway globally. The result is better transgene expression, safer delivery, and a plug-and-play approach that works across AAV, lentiviral, and other delivery formats. 0:00 Introduction 0:10 Welcome Jonathan Cohen-Gold, Houdini Bio 0:49 The problem: cells reject foreign DNA 1:39 Why this kills gene therapies 3:19 The market adoption crisis 4:42 Why previous approaches failed 5:11 The HUSH complex explained 6:15 Jonathan's PhD and unfair advantage 9:52 Building Houdini Bio from scratch 11:45 The Venture Science Doctorate 12:25 Academic system vs entrepreneurship 13:28 Houdini's platform and approach 14:00 Houdini elements explained 16:23 AI and the closed loop wet lab system 17:55 Current data and proof points 20:43 Rescuing failed gene therapies 22:18 What's next for Houdini Bio 25:22 The big opportunity 26:17 Investors and funding 29:19 Closing and what to watch for

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

Wesley Wierson and Alex Abel founded Leah Labs seven years ago around a pets-first model. When generative biology arrived, they designed something that no existing investor would fund. Animal investors won't back human-scale outcomes. Human investors won't back animal health companies. So VelociTx had to be built. Their CAR-T platform redesigns the transmembrane domain using a 2,000 de novo screen, finding 200 enriched candidates across 7 functional families, making CAR-T cells behave like TCR T cells to target solid tumors in ways nature never could. Wesley Wierson and Alex Abel are co-founders of VelociTx, a company using generative protein design to build the next generation of CAR-T cell therapy for solid tumors. Chapters 00:00:00 Welcome: Wesley Wierson + Alex Abel, VelociTx 00:00:58 Why VelociTx Had to Be Built 00:02:32 What If You Could Engineer a CAR Like a T Cell Receptor? 00:02:54 The Transmembrane Domain Discovery 00:06:34 The 2,000 De Novo Screen and What They Found 00:12:01 Going Into Lung Cancer First 00:15:51 How Generative Biology Changes Everything 00:27:35 What's Next in Biotech New episodes every Tuesday and Thursday at 11:00 AM 🚀

The biggest unsolved problem in cell therapy is donor variability. Why one patient's cells work and another's fail is a question the field still cannot answer. Alex Ward and Caelan Anderson, co-founders of Tolemy Bio, are building the intelligence layer that cell therapy has been missing. Their platform Orbit integrates all the process context around how cells are grown, managed, and manufactured to surface insights that nobody is currently leveraging. The goal is adaptive, patient-specific manufacturing across seventeen dimensions. Alex Ward and Caelan Anderson are co-founders of Tolemy Bio, a company building an AI-powered control panel for cell therapy manufacturing. Chapters 00:00:00 Welcome: Alex Ward + Caelan Anderson, Tolemy Bio 00:00:46 What Is Tolemy Bio and What Are They Building? 00:04:25 Why Do Some Patients' Cells Fail and Others Don't? 00:05:46 The Data Problem in Cell Therapy 00:14:00 The Control Panel for the Cell 00:15:15 Why Tolemy's Models Are Not Black Boxes 00:20:30 Adaptive Manufacturing Is the Future 00:25:34 What's Next in Biotech New episodes every Tuesday and Thursday at 11:00 AM 🚀

Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Today on the show: - 3 brand new startups in biotech that emerged from Stealth - 2 CEO interviews: one company is building a vaccine for tissue scarring, and the other, which just raised over $9M, turns solid tumors into therapeutic factories. Leave a comment if you have any questions - we try to get to them all!

This week, Innovian Space printed the first kidney and liver constructs in human history on the International Space Station. Jana Studemeier, CCO at Innovian Space, joins The Biotech Voyager to explain why gravity is the single biggest obstacle to printing functional organs, why microgravity solves it, and how the cost of a space experiment is nothing compared to the cost of a failed clinical trial. From Keytruda being reformulated using protein crystallization in space, to tumor organoids that behave more like real tumors in microgravity, to the coming explosion in regenerative medicine — this is the most unexpected biotech conversation we've had. Jana Studemeier is CCO at Innovian Space, a company helping organizations develop profitable and sustainable uses of space for biotech, pharma, and beyond. Chapters 00:00:00 Welcome: Jana Studemeier, Innovian Space 00:01:33 Printing Kidneys on the ISS This Week 00:03:10 Why Microgravity Changes Everything 00:06:26 Why 3D Printing Fails on Earth 00:10:23 Drug Testing With Tumor Organoids in Space 00:12:25 The Cost of Space vs Failing in Trials 00:19:18 Keytruda Was Reformulated Using Space 00:28:44 Space Will Cause a Regenerative Medicine Explosion New episodes every Tuesday and Thursday at 11:00 AM 🚀

Jay Kaplan, co-founder of Fractyl Health, joins The Biotech Voyager to explain why current GLP-1 drugs like Ozempic might have a worthy successor: a gene therapy that delivers GLP-1 directly to the pancreatic beta cells, only when you eat. Their lead program Rejuva-001 is already outperforming today's best pharmacology in animal models and has received first approval to begin clinical studies in the Netherlands. In this conversation, Jay breaks down the science behind their meal-responsive delivery mechanism, why a one-time gene therapy could replace chronic weekly injections, and what the future of gene therapy for large diseases looks like. Jay Kaplan is co-founder of Fractyl Health, a biotech company developing gene therapies that target the root causes of metabolic disease with the goal of curative treatments. Chapters 00:00:00 Welcome: Jay Kaplan, Fractyl Health 00:02:14 The Problem With GLP-1 Drugs 00:03:24 How the Gene Therapy Works 00:04:53 Ozempic vs. Meal-Responsive Therapy 00:05:35 Beating Pharmacology in Animal Models 00:07:39 Phase II Approved in Netherlands 00:07:56 One Shot. No Redosing. 00:10:39 Why Diabetes Needs a Cure 00:18:13 What's Next in Biotech New episodes every Tuesday and Thursday at 11:00 AM 🚀

YouTube Description: Non-viral gene delivery has always had one fatal flaw: it couldn't get DNA into the nucleus efficiently. LNPs top out at around 5% nuclear entry. SonoThera just hit 50% using ultrasound. Co-founder Ken Greenberg joins the show to break down exactly how they did it. We also cover AstroRx's embryonic stem cell-derived astrocyte therapy for MS, ANACA's TCR-T cell approach for solid tumors, Apligon's next-gen kinase inhibitor program, and Enterome's microbiome-based cancer therapy, plus the latest from the early stage biotech leaderboard at thebiotechvoyager.com. 0:00:00 Intro 0:00:51 Early Stage Biotech Leaderboard 0:02:20 Enterome: Microbiome Cancer Therapy 0:11:35 Ken Greenberg & SonoThera Preview 0:35:19 SonoThera Raises $125 Million 0:38:18 Apligon: Solid Tumor Kinase Inhibitors 0:44:34 ANACA: TCR-T Cell Therapy for Solid Tumors 1:00:34 AstroRx: Stem Cell Therapy for MS 1:02:43 Interview: Ken Greenberg, SonoThera 1:21:07 Sound Waves Delivering Gene Therapy 1:28:48 SonoThera Pipeline and Disease Targets New episodes every Tuesday and Thursday at 11:00 AM 🚀

Welcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

Welcome to The Biotech Voyager - it's the show that covers what's next in biotech.

The Biotech Voyager is the show that covers what's next in biotech.

The live show that covers what's next in biotech. Join us live!

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

ASGCT week moved fast. Too fast. So we’re doing a live aftershow on Monday, 11 AM to 12:30 PM EST to break down what happened at ASGCT 2026, the key insights, what surprised us, and what to watch next. Since this is a special one-off event, we will also stream this one live on Linkedin. We'll also have a special guest... so stay tuned. Come hang out with us. Add in your takeaways. See you there!

The Biotech Voyager is going live from 28 Capital's Back Bay offices on Monday to set the stage for ASGCT. We'll be covering the sessions, posters, and conversations worth your time this year, with guest appearances from NanoMosaic and Precede Bio sharing what they're bringing to the meeting. If you're heading to ASGCT or following from afar, tune in for a focused primer before the chaos begins.

Huge stories shaping the future of medicine this week. Researchers are using ultrasound to deliver gene therapy, bypassing traditional delivery methods entirely. Epigenetic editors are offering a new way to modify gene expression without cutting DNA. And a company developing gamma delta T cell engagers just closed an $83M Series A, a massive bet on a less explored branch of cancer immunotherapy. Ben and Jeff break down the science behind each story and what it means for the future of biotech. Tune in live Tuesdays and Thursdays at 11AM EST on The Biotech Voyager.

Diaconos Oncology just released new data in pancreatic cancer, one of the deadliest and hardest-to-treat cancers on the planet. But their approach isn't a typical drug. Ben and Jeff break down how dendritic cell vaccines work, why conventional cancer vaccines keep falling short, and what makes this approach different. Plus, RNA exon editing technology that rewrites disease at the RNA level without touching your DNA, and how AI is quietly transforming surgical pathology. New Episodes Monday, Tuesday and Thursday at 11am EST

In vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show. The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unpack why cancer vaccines are suddenly worth a second look after a decade in the wilderness. Then John Boyce from 28 Capital joins to talk early-stage biotech investing, what's catching his attention right now, and where he thinks the smart money is rotating in 2026.

Asgard's AT-108 might be the most insane immunotherapy of 2026. .. a first-in-class in vivo cell reprogramming play for cancer. Meanwhile, CNS gene therapy is having a moment: AviadoBio is crossing the blood-brain barrier, Avista's AI-designed capsids are heading to the eye and CSF, and Tenaya just dropped one-year cardiac gene therapy data at ASGCT. Plus: Dr. Nicole Paulk joins live! Her work on CNS-directed AAV gene therapy for glioma puts her right at the center of where this field is heading. Live on the Biotech Voyager. (Both YouTube and Linkedin)